Dr. Shaw is an experienced scientist and collaborator with a deep knowledge of the strategic development and implementation of biomarker and genomic platforms throughout drug development. Prior to his tenures at BMS and Merch, Dr. Shaw was an assistant professor at the NYU Langone Medical Center. He holds a Ph.D. in Drug Metabolism form the University of Aberdeen and A B.S. in Biochemistry from the University of Wales, Cardiff.
Peter’s expertise is in the strategic development, analysis and use, of pharmacogenetic and pharmacogenomic data for decision making in clinical and preclinical drug development. Peter’s achievements and focus include: identification and validation of genomic biomarkers, implementation of in life genotyping pipelines, development of ethical processes and procedures to protect privacy and collect clinical samples, globally, for genomic research, generation of data for regulatory filings and drug labels. Peter has collaborated with many functional groups (clinical, discovery, regulatory, legal and privacy) in and across most major therapeutic areas (Oncology, Infectious Disease, Cardiovascular, Diabetes and Neuroscience), to enable integration and application of pharmacogenomics. In addition, Peter has developed large strategic external relationships with academic centers and biotechnology companies to promote R&D, as well as contributed to multiple pre-competitive consortia programs and trade organizations to promote education and knowledge of pharmacogenetics: iPWG, SAEC, ACRG, PhRMA, EFPIA. Peter has over twenty years of experience at Merck & Co., Inc. and Bristol Myers Squibb which has led to numerous publications and patents.